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stone of science; yet, at times, reproduc-
ing the results of others can be a difficult
challenge. Our two laboratories, one on
the East and the other on the West Coast
of the United States, decided to collabo-
rate on a problem of mutual interest—
namely, the heterogeneity of the human
breast. Despite using seemingly identical
methods, reagents, and specimens, our
two laboratories quite reproducibly were
unable to replicate each other’s fluores-
cence-activated cell sorting (FACS) pro-
files of primary breast cells. Frustration
mounted, given that we had not found
the correct answer(s), even after a year.
Rather than giving up or each publishing
our data without the other laboratory, we
decided to work together to solve these
differences, even traveling from one
laboratory to the other in order to perform
experiments side by side on the same
human breast tissue sample. This ex-
ercise confirmed our suspicions and
resolved our problem. Here, we summa-
rize our cautionary tale and provide
advice to our colleagues.
The ever-increasing use of flow cytom-
etry and FACS in the past decade has
been accompanied by a surge of interest
in learning how to incorporate primary
normal breast tissues and breast tumors
in biomedical research. This interest in
primary-tissue-based research stems
from increased awareness that cell polar-
ity and shape, mechanical forces, and
tissue organization are all potent regula-
tors of cell and tissue phenotype, func-
tion, and physiology (for a review, see
Nelson and Bissell, 2006). Taking these
factors into account adds many more
dimensions to an already considerable
body of work on cellular heterogeneity of
breast tissues and its tumors. The height-
ened awareness of the critical importanceCell Rof studying cells close to their context
in vivo makes the exercise even more
challenging.
Paired with in situ characterizations,
FACS has emerged as the technology
most suitable for distinguishing diversity
among different cell populations in the
mammary gland. Flow instruments have
evolved from being able to detect only a
few parameters to those now capable
of measuring up to—and beyond—an
astonishing 50 individual markers per
cell (Cheung and Utz, 2011). As with any
exponential increase in data complexity,
the importance of developing robust
preparation and analytical protocols that
generate reproducible results increases
commensurately (Alexander et al., 2009;
Herzenberg et al., 2006). Here, we share
our surprising and time-consuming expe-
rience of trying to achieve similar data
sets in the East and West Coast settings
while collaborating on a shared grant.
The task at hand was to confirm each
other’s data so that we could move to
the next stage of collaboration. Given
that CD44 and CD10 are frequently used
as markers in most lineage and ‘‘cancer
stem cell’’ studies, and because there
are substantial disagreements and confu-
sion about the significance of what
FACS fractions from mammary gland
and breast tumors signify in different lab-
oratories, we paid special attention to
these two markers. A set of data that
was supposed to be completed in a few
months took 2 years to understand and
sort out.
Our challenges began when our two
laboratories, located in Boston and in
Berkeley, began our joint funded project
to study the involvement of myoepithelial
cells in breast tumor progression. An early
aim was to separate and characterize
cellular subpopulations derived fromeports 6, March 13, 2014 ª2014 The Authorsbreast reduction mammoplasties. Molec-
ular analysis of separated fractions
was to be performed in Boston (K.P.’s
laboratory, Dana-Farber Cancer Institute,
Harvard Medical School), whereas func-
tional analysis of separated cell popula-
tions grown in 3D matrices was to take
place in Berkeley (M.J.B.’s laboratory,
Lawrence Berkeley National Lab, Univer-
sity of California, Berkeley). Both our
laboratories have decades of experience
and established protocols for isolating
cells from primary normal breast tissues
as well as the capabilities required for
flow sorting primary cells from mice and
women.
We settled on isolating cell populations
independently in each laboratory in
order to avoid potentially adverse effects
caused by shipping freshly sorted cells
across the country (Figure S1A). We
carefully characterized antibodies for
CD24, CD10, and CD44 and gauged their
specificity. Because we were initially
interested in the nonluminal subfractions,
we were subtracting (gating out) the
CD24+ luminal cells on the cytometer
and analyzing CD10 and CD44 expres-
sion in the remaining subpopulations.
We quickly discovered, however, that
reproducing each other’s FACS profiles
would not be so straightforward. Despite
the fact that both groups began with
primary breast tissues from reduction
mammoplasty and the set of FACS pro-
files obtained in each laboratory was
consistently reproducible, the profiles
obtained in Boston and Berkeley were
not similar (Figure S1B). The question
was why.
A simple explanation could have been
that the FACS instruments used at each
institution differed: a FACSAria was used
in Boston, whereas a FACSVantage was
used in Berkeley. However, we quickly779Open access under CC BY-NC-ND license.
ruled out instrumentation as a source of
the problemby testing on each instrument
calibration beads and cell line standards
(mixtures of five breast cell lines with
distinguishable CD24, CD10, and CD44
levels; Figure S1C and data not shown).
Other possibilities we considered were
the specific sources of tissues (e.g., East
versus West Coast subjects and the
method of procurement), media composi-
tion, source of serum and additives, tissue
processing, and methods of staining cell
populations. We compared protocols
and ensured that we were using identical
enzymes, antibodies, and reagents by
either making purchases from identical
lots or shipping aliquots of different
reagents to each other. We did discover
slight differences in some parameters
and could quickly fix these. Still, tissues
processed in Boston always produced
the Boston profile and tissues processed
in Berkeley produced the Berkeley profile.
We were losing time and resources, and
we were perplexed.
The back and forth exchange lasted
about a year until we realized that, when
tissues were digested into organoids at
one location and shipped to the other
location to be separated and analyzed,
the resultant FACS profiles matched the
original institution where the collagenase
digestion of the tissue was performed.
This was an important clue.
With our attention focused on how we
were processing tissues, the two first
coauthors met in Berkeley to work side
by side so we could observe every step
of each other’s methods. With a fresh
specimen in hand, we diced and split the
tissue fragments into two equal parts
and prepared each half independently—
Boston versus Berkeley. The results
were surprising but clear: the two profiles
prepared from the same reduction
mammoplasty were different and bore
the signature of the respective laboratory
(Figure S1D)! However, this time-
consuming and expensive exercise gave
us the clue we had been waiting for: our
methods for incubating the collagenase
digests were distinctly different. In the
Boston method, tissue was being stirred
comparatively more vigorously in a flask
with a stir bar at a speed that achieved
constant agitation (300–500 revolutions
per min [RPM]) until the digest was
observed to be complete, which typically780 Cell Reports 6, March 13, 2014 ª2014 Thtook 6–8 hr. In the Berkeley method,
tissues were digested in 50ml tubes using
half the concentration of collagenase
used in Boston (1 versus 2 mg/ml) while
rocking relatively gently on a rotating plat-
form (80 RPM) and for a much longer time
(18–24 hr). We found that, in addition to
the distinct FACS profiles obtained by
each method of digestion, there was a
dramatic difference in the efficiency of
organoid recovery—roughly 53 more
organoids were recovered from the
slower and longer digest. We now had a
binary problem to solve: was it the colla-
genase concentration or the agitation
speed and length of digestion (or both).
To test this, we divided another fresh
tissue sample and digested it with the
two different enzyme concentrations but
with a slow/gentle agitation method for
both. This resulted in a similar (large) yield
of organoids and identical FACS profiles
(matching those from Berkeley; e.g.,
Figure S1B, right), thus identifying the
quality of agitation as the culprit.
We have reproduced these results
several times in each of our laboratories
and are confident that the speed and
length of agitation during the collagenase
digestion has a dramatic effect both on
organoid yield and CD44 antigen presen-
tation in the CD10+ cell fraction. Why this
is so awaits further experiments. One
possibility is that, in both of our methods,
organoids are further enzymatically
treated with trypsin in order to yield
single-cell suspensions. CD44 is notori-
ously sensitive to trypsin cleavage
(Camp et al., 1991; Takeda et al., 2006),
and different splice variants demonstrate
distinct sensitivities (Biddle et al., 2013).
However, neither trypsin nor collagenase
was the direct cause of the observed
differences here. Instead, it was the
vigorous agitation during collagenase
treatment itself that lead to reduced
CD44 antigen detection on the CD10+
cell population (CD44 levels were pre-
served on CD10 cells independently of
the agitation procedure used). Possible
explanations we have considered include
mechanical destruction of CD44 or
relevant epitopes, CD44 downregulation
or epitopes becoming cryptic during the
faster, more vigorous digest method, or
release of metalloproteinases or other
peptidases that cleave CD44 variants
on the CD10+ population. The methode Authors Open access under CC BY-NC-ND licenof agitation affects observed CD44, and
this sensitivity has obvious implications
for those optimizing their own digestion
protocols as well as for those depending
on CD44 antibodies to characterize
different cell subpopulations, such as
the widely used CD44+CD24 protocols
for isolating cancer stem cells. It is
important to emphasize that we did not
detect similar sensitivities for other
markers we use commonly, including
CD10, CD24, CD227, CD49f, CD90,
CD31, CD34, or CD45. It is educational
that CD44 staining used by countless
laboratories in FACS analysis can so
easily be altered by an apparently minor
difference in methodology. The irrepro-
ducibility of CD44 in FACS analysis has
become a legend. We expect sharing
these experiences demonstrates that
much can be learned through open
collaboration and persistence.
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